<DOC>
	<DOCNO>NCT02370043</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , effect food KQ-791 . Each participant may receive 3 single dos KQ-791 ( 3 different dose level ) 1 placebo dose course study . Up 6 escalate dose level may study , two distinct group cohort .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability , Pharmacokinetics Food-Effect KQ-791</brief_title>
	<detailed_description />
	<mesh_term>Insulin Resistance</mesh_term>
	<criteria>Male nonchildbearing potential female , include postmenopausal female ( absence menses 12 month prior drug administration , bilateral oophorectomy hysterectomy bilateral oophorectomy least 6 month prior drug administration ) surgically sterile female ( hysterectomy tubal ligation least 6 month prior drug administration ) Body Mass Index ( BMI ) great equal ( ≥ ) 27.0 less equal ( ≤ ) 35.0 kilogram per square meter ( kg/m2 ) Healthy define : 1. absence clinically significant illness surgery within last 4 week . Participants vomit within 24 hour predose evaluate upcoming illness/disease 2. absence clinically significant history neurological , endocrine , cardiovascular , pulmonary , hematological , immunologic , psychiatric , gastrointestinal , renal , hepatic , metabolic disease Male participant vasectomize least 6 month , sexually active nonsterile female partner ( sterile female partner include postmenopausal female surgically sterile female ) must willing use one follow acceptable contraceptive method throughout study 90 day last study drug administration : 1. simultaneous use condom , female partner hormonal contraceptive ( use since least 4 week ) intrauterine contraceptive device ( place since least 4 week ) 2. simultaneous use male condom , female partner , diaphragm intravaginally apply spermicide Some degree insulin resistance , show : 1. fast blood glucose ≥95.4 ≤126 milligram per deciliter ( mg/dL ) ( equivalent 5.3 7.0 millimoles per liter ( mmol/L ) , respectively ) 2. fast triglyceride ≤ 4.0 mmol/L , and/or 3 . LowDensity Lipoprotein Cholesterol ( LDLC ) ≤ 6.0 mmol/L Capable consent Nonsmoker ( use tobacco product within last 3 month ) Any clinically significant abnormality abnormal laboratory test result ( glucose , triglyceride LDLC level describe inclusion criterion ) Positive test hepatitis B , hepatitis C , Human Immunodeficiency Virus ( HIV ) Evidence clinically significant hepatic renal impairment , include Alanine Aminotransferase ( ALT ) 1.5x Upper Limit Normal ( ULN ) , Aspartate Aminotransferase ( AST ) 2x ULN , total bilirubin 2x ULN ( total bilirubin accept 2x ULN direct bilirubin within normal limit ) , Estimated Glomerular Filtration Rate ( eGFR ) less ( &lt; ) 90 milliliter per minute ( mL/minute ) Positive urine drug screen History significant allergic reaction ( e.g . angioedema ) drug . Use drug know induce inhibit hepatic drug metabolism within last 30 day Positive pregnancy test Any reason , opinion qualify investigator ( QI ) would prevent subject participate study Clinically significant electrocardiogram ( ECG ) abnormalities screen , clinically significant personal family history ( firstdegree relative ) heart disease , include : 1 . Confirmed corrected QT ( QTcF ) interval great ( &gt; ) 450 millisecond ( msec ) men woman 2 . Bundle branch block conduction abnormality mild first degree atrioventricular block 3 . Irregular rhythm sinus arrhythmia occasional , rare supraventricular ectopic beat History unexplained syncope Family history unexplained sudden death sudden death due long QT syndrome Twave configuration sufficient quality assess QT interval Clinically significant vital sign abnormality ( systolic blood pressure low 90 150 mmHg , diastolic blood pressure low 50 95 mmHg , heart rate less 50 100 beat per minute ( bpm ) ) History significant alcohol abuse within one year prior screen regular use alcohol within six month prior screen ( regular use three unit alcohol per day male two unit alcohol per day female [ 1 unit = 150 ( milliliter ) mL wine , 360 mL beer , 45 mL 40 % alcohol ] ) positive alcohol breath test History significant drug abuse within last year use soft drug ( marijuana ) within 3 month prior , hard drug ( cocaine , phencyclidine ( PCP ) crack ) within last year Participation clinical trial involve administration investigational market drug within last 30 day ( 90 day biologics ) concomitant participation investigational study Use medication topical product without significant systemic absorption : 1. prescription medication within last 14 day 2. overthecounter product within last 7 day , exception occasional use acetaminophen ( 2 gram ( g ) daily ) 3. natural health product ( e.g . food supplement herbal supplement ) within last 14 day 4. depot injection implant drug within last 3 month Donation plasma within last 7 day . Donation loss blood 50 mL 499 mL blood within 30 day , 499 mL within 56 day Hemoglobin &lt; 128 gram per liter ( g/L ) ( male ) &lt; 115 g/L ( female ) hematocrit &lt; 0.37 L/L ( male ) &lt; 0.32 L/L ( female ) Breastfeeding participant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>